Form 4: Revolution Medicines Executive Sells Shares
Insider Transaction (Form 4)
Alan B. Sandler, Chief Development Officer of Revolution Medicines, Inc., sold 341 shares of common stock on September 16, 2026.
Summary
- Open-market sale: disposed of 5 Common Stock at $194.96 ($975) on September 16, 2026; holds 53,204 after (Direct).
- Open-market sale: disposed of 336 Common Stock at $199.30 ($66,966) on September 16, 2026; holds 52,868 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $67,941 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Alan B. Sandler — Officer (Chief Development Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-16 | Open-market sale | Common Stock | 5 | $195 | $975 | 53,204 |
| 2026-09-16 | Open-market sale | Common Stock | 336 | $199 | $67.0K | 52,868 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-16 | Open-market sale (5 shares) |
| 2026-09-16 | Open-market sale (336 shares) |
Keywords
insider transaction, Form 4, RVMD, Revolution Medicines, Inc., bearish, Alan B. Sandler
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.